XBiotech grants director 79,115 nonstatutory options at $2.64

Rhea-AI Filing Summary

XBiotech (XBIT) reported a director equity grant. On October 1, 2025, the reporting person received 79,115 nonstatutory stock options to purchase common stock at an exercise price of $2.64, equal to the closing sale price on the grant date. The options vest in two equal portions at four months and ten months from the grant date and carry a 10-year expiration. The filing lists the holder’s relationship as Director and shows direct (D) ownership.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Kuendig Thomas Martin

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Director Stock Option	79,115	$0.00	--

Holdings After Transaction: Director Stock Option — 79,115 shares (Direct)

Footnotes (1)

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kuendig Thomas Martin

(Last) (First) (Middle)

ALPENSTRASSE 23

8803 RUESCHLIKON, KANTON OF ZUERICH

(Street)

RUESCHLIKON V8 8803

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
XBiotech Inc. [ XBIT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option	$2.64	10/01/2025		A		79,115		02/01/2025	10/01/2035	Common Stock	79,115	$0	79,115	D

Explanation of Responses:

Remarks:

On October 1, 2025 (the Grant Date) the reporting person was granted nonstatutory stock options (the Options) under the Company's 2025 Equity Incentive Plan to purchase shares of the Company's Common Stock (the Shares) at an exercise price equal to the closing sales price of the Shares on the Grant Date as quoted by the Nasdaq Stock Market. The Options vest in two equal portions at four month and ten month from the Grant Date with an expiry of ten years from the Grant Date.T

	Thomas Kuendig	11/12/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did XBiotech (XBIT) disclose in this Form 4?

A director was granted 79,115 nonstatutory stock options on October 1, 2025 at an exercise price of $2.64.

What is the exercise price of the options granted by XBIT?

The exercise price is $2.64, stated as equal to the closing sales price on the grant date.

How do the XBiotech options vest?

They vest in two equal portions at four months and ten months from the grant date.

What is the term of the granted options at XBiotech?

The options expire ten years from the grant date.

What is the reporting person’s relationship to XBiotech?

The reporting person is a Director.

Under which plan were the options granted?

They were granted under the company’s 2025 Equity Incentive Plan.

What ownership form is indicated in the filing?

The filing indicates direct (D) ownership of the derivative securities.